Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer


Corporate Profile

Castle Creek Biosciences, Inc. is a privately held, clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from orphan conditions where there are high unmet needs due to a lack of available treatment options. The company is using its proprietary fibroblast technology platform to develop D-Fi (dabocemagene autoficel, formerly known as FCX-007), an investigational, cell-based gene therapy for the localized treatment of dystrophic epidermolysis bullosa (DEB). The company is also developing FCX-013, an investigational, cell-based gene therapy for the treatment of moderate to severe localized scleroderma. The company operates an in-house, commercial-scale facility located in Exton, Pennsylvania, which is desigend to be current good manufacturing practices-compliant (cGMP). Castle Creek Biosciences is a portfolio company of Paragon Biosciences.